Equity Profile

SLNO

Soleno Therapeutics, Inc.

Health CareBiotechnology$2.8B

Mar23Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Soleno Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

N/A

Revenue Growth

Revenue growth is critical for assessing how well the company is expanding its market presence and product adoption.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SLNO Q2-2026 Earnings Preview

Context

Company Snapshot

Soleno Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases. Operating in the health care sector, it aims to address unmet medical needs, which is increasingly important as the demand for specialized treatments grows.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+1923.32%

Avg Stock Reaction

-0.32%

Last Quarter Recap

In Q1 2026, Soleno reported an EPS of $0.59, which was below the expected $0.73, leading to a slight stock increase of 0.02% the following day. The company did not provide revenue figures or specific guidance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has shown a tendency to surprise on EPS, but the lack of revenue guidance raises uncertainty. Investors will be keen to see if Soleno can maintain its positive surprises.

Bull Case

If Soleno can deliver better-than-expected EPS and show strong revenue growth, it could signal robust demand for its therapies and lead to a positive stock reaction.

Bear Case

Conversely, if the company misses on EPS again or fails to provide clear guidance on revenue, it could raise concerns about its growth trajectory and negatively impact the stock.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to previous quarters?

Given the company's mixed EPS history, this will be crucial for investor confidence and stock performance.

Will there be any guidance on revenue growth for the upcoming quarters?

Clear revenue guidance is essential for assessing the company's future prospects and market strategy.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Soleno's potential for a strong rebound in EPS, given its historical ability to surprise on the upside despite recent misses.

Supporting Evidence

The company has a 63% EPS beat rate, indicating a strong potential for positive surprises.

Options are pricing a 5.47% move, suggesting traders expect significant volatility, which could favor a positive outcome.

Key Risk

If EPS comes in above $0.75, it could shift sentiment dramatically, contradicting the cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be pivotal in determining whether Soleno can sustain its previous growth trajectory amidst market challenges.

Bull Confirmed If

An EPS of $0.75 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.50 would raise serious concerns about the company's growth and profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±5.47%

Historical Avg

±2.0%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±5.5% while SLNO has averaged ±2.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

81.0%

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Soleno beats expectations, history suggests the stock could rise by around 0.2%, confirming a positive outlook for growth.

In-Line / Cautious

If results are in line with expectations, the stock might see muted reactions as investors await further clarity from management.

Miss

A miss could lead to a decline, with history indicating an average drop of around 0.2% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the pipeline of therapies and their expected market launch dates.
2Details on R&D spending and how it aligns with future growth strategies.
3Insights into market demand for current products and any new partnerships.
4Management's outlook on competitive pressures in the biotechnology sector.
5Any commentary on regulatory developments that could impact product approvals.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

PDD Holdings Inc.

Company Snapshot

Soleno Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

N/A

Revenue Growth

Revenue growth is critical for assessing how well the company is expanding its market presence and product adoption.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SLNO Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+1923.32%

Avg Stock Reaction

-0.32%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Soleno can deliver better-than-expected EPS and show strong revenue growth, it could signal robust demand for its therapies and lead to a positive stock reaction.

Bear Case

Conversely, if the company misses on EPS again or fails to provide clear guidance on revenue, it could raise concerns about its growth trajectory and negatively impact the stock.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to previous quarters?

Given the company's mixed EPS history, this will be crucial for investor confidence and stock performance.

Will there be any guidance on revenue growth for the upcoming quarters?

Clear revenue guidance is essential for assessing the company's future prospects and market strategy.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Soleno's potential for a strong rebound in EPS, given its historical ability to surprise on the upside despite recent misses.

Supporting Evidence

The company has a 63% EPS beat rate, indicating a strong potential for positive surprises.

Options are pricing a 5.47% move, suggesting traders expect significant volatility, which could favor a positive outcome.

Key Risk

If EPS comes in above $0.75, it could shift sentiment dramatically, contradicting the cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be pivotal in determining whether Soleno can sustain its previous growth trajectory amidst market challenges.

Bull Confirmed If

An EPS of $0.75 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.50 would raise serious concerns about the company's growth and profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±5.47%

Historical Avg

±2.0%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±5.5% while SLNO has averaged ±2.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

81.0%

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Soleno beats expectations, history suggests the stock could rise by around 0.2%, confirming a positive outlook for growth.

In-Line / Cautious

If results are in line with expectations, the stock might see muted reactions as investors await further clarity from management.

Miss

A miss could lead to a decline, with history indicating an average drop of around 0.2% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the pipeline of therapies and their expected market launch dates.
2Details on R&D spending and how it aligns with future growth strategies.
3Insights into market demand for current products and any new partnerships.
4Management's outlook on competitive pressures in the biotechnology sector.
5Any commentary on regulatory developments that could impact product approvals.